‘Revolutionary’ LDL lowering shown in evolocumab phase III trials

WASHINGTON – The novel low-density lipoprotein cholesterol–lowering agent evolocumab took day 1 of the annual meeting of the American College of Cardiology by storm on the strength of three...

Field of Interest: Cardiology